Introduction
Amyloid is a product of protein misfolding that results in extensive b-pleated sheet formation, which, in turn, is responsible for its affinity to the Congo red stain. Under polarized light, Congo red stained deposits exhibit an apple green birefringence, which is diagnostic of amyloid. By electron microscopy, amyloid is composed of fibrils 8-12 nm thick and of indefinite length [1] . Disease processes associated with amyloid formation -the amyloidoses -comprise a group of disorders of diverse cause: acquired or hereditary, neoplastic, infectious, degenerative or associated with ageing [1, 2 ] . Amyloid deposits can be derived from more than 25 different types of proteins and many more variants; additional types of amyloid protein and variants are likely to be discovered in the future. The current classification of amyloid is based upon the amyloid fibril protein type, also referred to as the precursor protein [1] . By convention, the amyloid type is designated A followed by an abbreviation derived from the name of the amyloid fibril precursor protein [1] . Amyloidosis can be cerebral or extracerebral, systemic, localized or localized and systemic [1,2 ,3, 4 -6 ,7,8 ,9
]. This review focuses on recent developments in the area of extracerebral systemic amyloidoses.
Systemic amyloidoses: overview AL (also known as primary) amyloidosis is derived from the immunoglobulin light chain or, more frequently, a fragment thereof [2 ,3,4 -6 ,7,8 ,9 ]; rare forms of amyloid derived from truncated immunoglobulin g or m-heavy chain (termed AH) have also been reported [10] [11] [12] . AL-amyloidosis is associated with various B cell lymphoproliferative disorders encompassing the multiple myeloma-plasma cell dyscrasia spectrum and, on occasion, with malignant lymphomas and macroglobulinemia [13] . It is postulated that aminoacid substitutions in the light (or heavy) chain render them amyloidogenic. In the United States and the Western world, AL-amyloidosis is the most prevalent type of systemic amyloidosis [2 ,3,4 -6 ,7,8 ]. Tumor-like, localized, AL-type deposits may be seen in some patients [14, 15] .
AA amyloidosis (formerly known as secondary) is more common in developing countries than AL-type [2 ,4 ,16] accounting for an estimated 45% of all systemic amyloidoses worldwide. Typically, AA amyloidosis is associated with ('secondary to') a chronic inflammatory process such as the chronic inflammatory arthritides (in the developed world) and long-standing infections (in developing countries) [16, 17] ; an association with drug users and AIDS has also been reported [18, 19] . Amyloid is derived from the serum protein precursor, SAA, which is typically upregulated in chronic inflammatory processes. Amyloid A protein is a product of incomplete proteolytic digestion of SAA [16] .
Patients on long-term dialysis may develop amyloidosis derived from b 2 -microglobulin (Ab 2 -m) [20, 21] .
Diversity of systemic amyloidoses: beyond AL and AA and the expanding role of genetics Hereditary amyloidoses are being diagnosed with increasing frequency [22, 23] , yet recent data suggest that they are still underdiagnosed. Although these amyloidoses are autosomal dominant, the phenotype may vary significantly due to differences in gene penetration; de-novo mutations may also occur in some patients [24, 25] . Hence, a family history may be missing and the clinical picture may mimic AL-type [24] . Thus, lack of awareness of the condition and the absence of a family history have had a major impact on substantial underdiagnosis. Although amyloid derived from tranthyretins (ATTR) was initially diagnosed in Portugal, Sweden and Japan, it is now recognized that ATTR is not limited to these geographic locations [22] [23] [24] 26] . Presently, ATTR is the most common type of hereditary amyloidosis in the US [22] . Currently, over 100 mutations of transthyretin have been identified. Transthyretin circulates as a tetramer and is responsible for thyroid hormone transport and the binding of retinol. The presence of a mutant of the protein destabilizes the tetramer and leads to the release of monomers, which are believed to be amyloidogenic. Although ATTR is systemic, it is typically associated with polyneuropathy and cardiac involvement (more severe with some mutants) while renal involvement may be clinically silent. In some ATTR mutants, however, nephropathy may be present, leading to renal failure [27, 28] .
Interestingly, in elderly patients, the wild-type transthyretin may cause senile cardiac amyloidosis (SCA) [29] [30] [31] . Survival in SCA is significantly longer than in AL-type patients with cardiac involvement [31] . While SCA amyloid deposits may be systemic, extracardiac deposits (including renal) are usually clinically silent.
Amyloid derived from the fibrinogen A a chain (AFib) appears to be the most common form of hereditary amyloidosis in the UK and northern Europe [23, 24, 32] . Amyloid deposits in AFib are quite unique in that they appear to selectively target glomeruli and lead to their complete obliteration, with sparing of the extraglomerular compartments. Renal failure rapidly develops (Fig. 1 ).
In patients with systemic amyloidosis, presenting with renal, gastrointestinal or bleeding complications, amyloid derived from a mutant of lysozyme (ALys) should be considered [33, 34] . In amyloidosis derived from apolipoprotein AI (AApo AI), deposits are typically extraglomerular, medullary and associated with renal failure rather than proteinuria (Fig. 2) [35] . Other types of amyloidosis affecting the kidney are listed in Table 1 [1,9 ,22-24, 26-29,31-37,38
,39]. Although most of the hereditary amyloidoses can affect the kidney, the development of renal damage varies, ranging from slow to rapid progression to renal insufficiency; in some cases, deposits of amyloid may be clinically silent [32] .
Genetics may play a role in other types of amyloidosis as well. An association between familial Mediterranean
New insights into systemic amyloidosis Picken 197 Figure 1 Kidney biopsy from a patient with amyloidosis derived from the Glu526Val variant of fibrinogen A a-chain (a) Glomeruli are largely replaced by Congo red positive deposits. In contrast, the extraglomerular vessels and interstitium show little amyloid. These deposits were also birefringent when viewed under polarized light (not shown). Congo red stain, original mag. x100. (b) Immunohistochemical stain for fibrinogen is positive within the deposits of amyloid (original mag. x100). Reprinted with permission [24] . fever (FMF) and AA amyloidosis has been recognized for a long time [38 ,39-41] . Only recently, however, have the underlying genetic factors been understood [38 ] . FMF is a prototype of the familial periodic fevers, also known as auto-inflammatory syndromes. Periodic fevers represent the recently expanding spectrum of chronic, recurrent inflammatory disorders associated with genetic defects in various enzymes involved in innate immunity (i.e. not associated with autoantibodies or antigenspecific T-cell activation). While some are recessive, others are autosomal dominant. Most patients have mutations in either pyrin, cryopyrin or the tumor-necrosis factor (TNF) receptor genes [38 ,39-41] . Systemic AA amyloidosis develops in a subset of these patients with varying frequency, depending on the type of mutation [38 ,39-41] .
FMF has been associated with the Mediterranean basin, while several other periodic fevers were detected in northern Europe. Recently, however, additional FMF and other periodic fever patients have been identified throughout Europe and the US [38 ,39-43] . Periodic fevers are likely to have been underdiagnosed. The availability of genetic testing, and increased awareness, have led to an increased recognition of these disorders. Recently, genetic defects in genes involved in innate immunity have been demonstrated in several patients who developed AA amyloidosis, seemingly without evidence of an underlying chronic inflammation [17] .
Advances in treatment of systemic amyloidoses
In recent years, management of amyloidosis has undergone a formidable evolution: it has shifted from a purely supportive approach to quite diverse, radical and aggressive treatments [44, 45 ] . The central issue is the understanding that treatment of systemic amyloidoses depends on the molecular type of the amyloid protein. [29, 31] . c Genetic defect involving the amyloid protein precursor [1, 22] . d Polyneuropathy and cardiomyopathy, some mutants with severe renal involvement [26] [27] [28] . e Severe nephropathy with glomerular involvement [24] . f Hepatic involvement, cardiomyopathy, nephropathy with involvement of renal medulla, some mutants with neuropathy [35] . g Nephropathy [32, 36] . h Gastrointestinal involvement, nephropathy [33, 34] . i Cutis laxa, cranial neuropathy, renal failure in homozygotes [37] . j Clinically silent [23] . [48] [49] [50] . These regimens have been shown to control the underlying plasma cell dyscrasia leading to a reduction in the level of free serum light chains; a gradual improvement in the function of affected organs also occurs [51] [52] [53] . Treatment outcomes are better with early therapy and in patients with preserved renal function [6 ,44] . Owing to significant treatment-related mortality and morbidity, patient selection for treatment has to be rigorous. In the past, patients over 65 years old and patients with cardiac amyloid were considered unsuitable for such a high risk therapy. Recently, however, patients over 65 years old were also successfully treated with a risk-adapted therapy [54] . Moreover, for patients with cardiac AL amyloidosis, sequential heart and autologous stem cell transplantation have been tried [55] . Living donor kidney and autologous stem cell transplantation for AL amyloidosis with predominant renal involvement was recently reported [56] . A consensus definition of organ involvement and treatment response in AL-type was also recently published [57] .
Since the early 1990s, liver transplantation has been offered to patients with ATTR; the rationale being that, since the liver was the main source of abnormal protein, its surgical replacement by an organ that produces normal transthyretin, should cure the condition [58] . Given the relatively high morbidity associated with liver transplantation, surgery was initially offered only to patients with established disease. It is now, however, widely recognized that better results can be achieved in patients who are transplanted at an early stage of amyloidosis [59, 60] . In patients with severe cardiac or renal involvement, liver transplantation was combined with heart or kidney transplantation. Interestingly, heavy amyloid deposits in the kidneys, especially in the glomeruli, may portend a poor outcome for liver transplantation [61] . Thus, kidney biopsy has been proposed as an outcome predictor for liver transplantation. Hepatorenal transplantation has also been successfully offered to patients with hereditary amyloidosis derived from apolipoprotein AI, apolipoprotein AII and fibrinogen, with excellent results [36, 62, 63] .
Nonsurgical therapies are also being developed for ATTR [64] [65] [66] . Several small molecules have been identified that can stabilize the transthyretin tetramer in the presence of mutant subunits and thus prevent the release of pathogenic monomers. Currently, one such molecule -diflunisal -is in clinical trial [65] .
In AA amyloidosis, control of the underlying infection is currently the standard of care. A new therapy, however, is also being tested in a clinical trial. A small molecule (eprodisate disodium, Kiacta TM, formerly Fibrillex TM) has been shown, in vivo, to inhibit fibrillogenesis [67] .
In FMF, colchicine has been effectively used for decades to control the inflammatory response and prevent AA amyloidosis [41] . In other periodic fevers, biologic response modifiers, such as inhibitors of TNF and IL-1b, are being tested [68] .
Localized amyloid deposits, which may be encountered in various organs, do not warrant systemic treatment [14, 15] .
Diagnosis of amyloidosis: detection and typing
Congo red stain continues to be the gold standard in the diagnosis of amyloid (reviewed [2 ,9 ]). Clearly, more sensitive and easier screening methods for the diagnosis of amyloid are needed. In this connection, preliminary studies [69] reporting the application of an amyloid chip to generic detection of amyloid in tissue biopsy samples are interesting.
It must be stressed that potassium permanganate stain currently has no role in amyloid typing. Immunohistochemical diagnosis of AA-type is relatively reliable; the biggest challenge is in the diagnosis and differentiation of AL and hereditary amyloidoses [3,5
,44].
In AL-type, due to light chain truncation, amyloid fibril proteins may be composed of a variable region that is largely devoid of the constant region fragment. Such proteins may be nonreactive with commercial antibodies, which are typically raised against the C region. Thus, it may be anticipated that not all AL amyloid deposits will be reactive with commercial antibodies for k or l light chains [9 ] .
Review of recently published series [9 , 24, [70] [71] [72] shows quite a wide range of success in immunohistochemical amyloid typing, ranging from 38 to 87%. Interestingly, other antibody-based techniques, such as immunoelectron microscopy and Western blotting, have been shown to yield better results than immunohistochemistry [73, 74, 75 ]. Thus, antigenic preservation appears to play some role. The second issue is that of 'contamination' by serum proteins, which may create a background stain.
Interestingly, reports from nonrenal referral centers show a lower rate of success. While this may be, in part, a consequence of more stringent diagnostic criteria, technical issues should also be considered. Thus, amyloid typing in frozen tissue, typically used in renal pathology, yield much better results, with success rates between 65 and 87% [9 , 71, 72] . In the author's own experience, background 'contamination' with serum proteins is much less bothersome in frozen sections (Figs 3 and 4) . Therefore, immunofluorescence is the technique of choice for typing amyloid derived from immunoglobulin light and heavy chains and, indeed, amyloid in general [2 ,9 ,72].
In order to compensate for background stain, the use of a panel of antibodies is recommended in that it provides an opportunity to identify the strongest antibody reaction. The choice of antibodies in a panel should be a reasonable compromise between the ever-increasing diversity of amyloidoses, their clinical relevance in terms of available treatments, the volume of testing and the availability of adequate controls [2 ,9 ] . It is also clear, however, that even for a first attempt at amyloid typing, antibodies against the most common hereditary amyloidoses -ATTR and AFib -should be included. In fact, ATTR is the second most common type of amyloid diagnosed in myocardial and peripheral nerve biopsies.
Recently, the importance of discrimination between AL and hereditary amyloidoses has been recognized. Two studies [24, 76 ] have demonstrated that hereditary amyloidosis may bemisdiagnosedasAL in some patients.Inone series [24] of 350 patients with a presumptive diagnosis of AL amyloidosis and the absence of a family history, 10% of patients were shown to have familial amyloidosis. Twentyfour percent of these patients also had a low-grade monoclonal gammopathy. In a study by Comenzo et al. [76 ] , 6% of screened patients and 2% of asymptomatic patients had both a monoclonal gammopathy and a mutation in an amyloidogenic protein. Thus, it is currently recognized that the exclusion of other types of amyloid is an important part of the work-up in patients with amyloidoses [24, 76 ].
It has also been shown that the presence of a mutation within the sequence of an amyloidogenic protein does not necessarily indicate that the amyloid in the patient is derived from that mutated protein. To this end, patients with proven AL amyloidosis, who also had mutations in one of the amyloidogenic proteins, were recently reported [77] ; examples of AL, diagnosed in a clinical setting suggestive of AA amyloidosis, have also been demonstrated [78] [79] [80] . Thus, it is imperative that the criteria for amyloid-type diagnoses be stringent. Biochemical typing of amyloid protein extracted from formalin-fixed, paraffin-embedded specimens has been tried for several years [81] . Most recently, the application of proteomics techniques to amyloid typing has been reported [82 ,83] . This requires lesser amounts of material for study, but at the expense of complexity of preparation. While such studies are feasible in paraffinembedded biopsies, fresh, unfixed tissue is preferable. Interestingly, adipose tissue may be a reasonable source of such samples [84 ] .
Although these sophisticated (and labor intensive) techniques are currently available only in highly specialized research laboratories, and have not yet been validated in large numbers of samples in multiple centers, their development is certainly a welcome advancement. While it is appealing to see the future of amyloid diagnosis in proteomics, the question arises as to whether amyloid proteomics is ready for prime time now [85 ,86 ] .
Conclusion
The clinical relevance of diagnosis of amyloidosis cannot be overestimated. As the treatment options expand, there is increasing need for early diagnosis and accurate amyloid typing. Currently, immunohistochemistry is the standard technique used for typing of amyloid. It is critical that amyloid typing is done properly. In inconclusive cases, additional studies, best performed in specialized centers, are needed.
Since amyloid is essentially a protein disorder, proteomics methodologies are emerging as applicable diagnostic tools, despite their inherent complexities.
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